Health Care [ 2/12 ] | Pharmaceuticals [ 6/73 ]
NASDAQ | Common Stock
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough.
The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF; phase 2 clinical trial in patients with pruritus; and phase 2b/3 clinical trial in patients with prurigo nodularis.
Trevi Therapeutics, Inc. has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations.
The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 7, 25 | -0.09 Increased by +25.00% | -0.10 Increased by +10.00% |
| May 5, 25 | -0.09 Increased by +18.18% | -0.09 |
| Mar 18, 25 | -0.11 Decreased by -37.50% | -0.12 Increased by +6.06% |
| Nov 6, 24 | -0.13 Decreased by -62.50% | -0.12 Decreased by -8.33% |
| Aug 8, 24 | -0.12 Decreased by -71.43% | -0.11 Decreased by -9.09% |
| May 7, 24 | -0.11 Decreased by -83.33% | -0.09 Decreased by -22.22% |
| Mar 20, 24 | -0.08 Decreased by -33.33% | -0.09 Increased by +11.11% |
| Nov 9, 23 | -0.08 Increased by +33.33% | -0.09 Increased by +11.11% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 0.00 Decreased by N/A% | -12.30 M Increased by +0.41% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -10.34 M Increased by +5.16% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 146.00 K Decreased by -17.05% | -11.41 M Decreased by -45.95% | Decreased by -7.82 K% Decreased by -75.94% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -13.24 M Decreased by -72.02% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -12.35 M Decreased by -72.88% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -10.90 M Decreased by -70.32% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 176.00 K Increased by +N/A% | -7.82 M Decreased by -42.10% | Decreased by -4.44 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -7.70 M Increased by +6.87% | Decreased by N/A% Decreased by N/A% |